Multiple Myeloma Clinical Trial
Official title:
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
Primary Objectives: - In Phase I, define the toxicities and recommended Phase II dose (RP2D) of belumosudil mesylate in a population of patients with relapsed/refractory multiple myeloma. - In Phase II, obtain preliminary evidence of efficacy of belumosudil mesylate and further expand the safety experience in this patient population. The overall response rate (ORR) will be defined using the International Myeloma Working Group Uniform Response Criteria as the proportion of patients who, on an intent-to-treat basis, achieve at least a partial response (PR) or better on either belumosudil mesylate alone, or with dexamethasone. - In Phase II, obtain preliminary evidence of efficacy of the combination of belumosudil mesylate with dexamethasone, with the ORR defined as above. Secondary Objectives: - Examine the clinical benefit response rate (CBR), defined as patients experiencing at least a minimal response (MR) or better on belumosudil mesylate alone, and on belumosudil mesylate with dexamethasone. - Examine the disease stabilization rate (DSR), defined as patients experiencing at least stable disease (SD) or better on belumosudil mesylate alone, and on belumosudil mesylate with dexamethasone. - Determine durability of responses to single agent belumosudil mesylate, and/or in combination with dexamethasone, including the progression free survival (PFS), minimal residual disease (MRD) negativity in patients achieving a very good partial remission (VGPR) or complete response (CR), duration of response (DOR), and time to next treatment (TTNT). - Compare the MRD, response, and durability of therapy in patients with standard- and high-risk disease defined by FISH. - Evaluate the impact of therapy and symptom burden with single agent belumosudil mesylate alone, and of belumosudil mesylate with dexamethasone, on patients with relapsed/refractory multiple myeloma on patient-reported outcomes using the European Organization for Research on the Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (QLQ-C30). Exploratory/Correlative Study Objectives: - The baseline bone marrow sample will be separated into CD138+ and CD138- fractions, and the former will be examined by single cell RNA sequencing (scRNA-Seq) and singe cell B-cell receptor sequencing (scBCR-Seq). Also, the CD138- fraction will be examined by scRNA-Seq, scBCR-Seq, and singe cell T-cell receptor sequencing (scTCR-Seq). Our exploratory objectives are to characterize the myeloma cell's transcriptomic profile, including expression levels of ROCK1 and ROCK2, as well as activation status of the IL-6 pathway to then correlate these to any responses that will be seen. - The pre-Cycle 3 bone marrow sample will be similarly processed and analyzed. Our exploratory objectives here will be to characterize the transcriptional changes induced by belumosudil mesylate in the myeloma cells themselves, and also the change in the tumor microenvironment (TME), including in the infiltration by, and activation status of immune effector cells. - Correlate Th17 and regulatory T-cell activation and interleukin level (IL-4, IL6-, IL-17, IL-21, IL-22, and IL-23) changes in myeloma. - To explore the utility of a CMMC assay in monitoring myeloma disease burden and response kinetics. - To explore the potential of MicroOrganoSphereTM (MOS) technology to predict clinical ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |